Greenwich LifeSciences

About Greenwich LifeSciences

Greenwich LifeSciences, Inc. (GLSI) is a clinical-stage biopharmaceutical company focused on developing GLSI-100, an immunotherapy vaccine designed to prevent breast cancer recurrences in HER2-positive patients by activating the immune system.

Products & Services

GLSI-100:A first-of-its-kind immunotherapy vaccine combining GP2 (a HER2/neu-derived peptide) with GM-CSF, aimed at preventing breast cancer recurrence in HER2-positive patients, currently in a Phase III clinical trial (Flamingo-01).

GLSI-100

Specialties

Immunotherapy Breast Cancer Prevention HER2-positive Cancer Treatment Clinical Trials HER2-positive breast cancer immunotherapy Cancer vaccine development Phase III clinical trials

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: ATM Offering T: - FT: ATM Offering	A: 10500000 MR: - FA: approximately $10.5 million FAN: 10500000	D: 2026-04-14 FD: 2026-04-14	-
2	RT: Equity Financing T: - FT: Equity Financing	A: 7000000 MR: - FA: approximately $7 million FAN: 7000000	D: 2026-01-27 FD: 2026-01-27	2 investors
3	RT: Private Placement T: - FT: Private Placement	A: 2500000 MR: - FA: $2.5 million FAN: 2500000	D: 2024-06-14 FD: 2024-06-14	1 investors

ATM Offering Latest

2026-04-14

$10.5M

Equity Financing 2026-01-27

$7.0M

Private Placement 2024-06-14

$2.5M

View 2 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

F

F. Joseph Daugherty

Chief Medical Officer, Board Member

K

Kenneth Hallock

Board Member

Recent News